April 2012 Drug Information Update - Pharmacy Benefits ...

More documents

Recommendations

Info

Products Affected - Description Etoposide solution for injection, 20 mg/mL, Accord 5 mL vial (NDC 16729-0114-31) Etoposide solution for injection, 20 mg/mL, Bedford 5 mL vial (NDC 55390-0291-01) 25 mL vial (NDC 55390-0292-01) 50 mL vial (NDC 55390-0293-01) 5 mL Novaplus vial (NDC 55390-0491-01) 25 mL Novaplus vial (NDC 55390-0492-01) 50 mL Novaplus vial (NDC 55390-0493-01) Reason for the Shortage • Teva had etoposide on shortage due to manufacturing delays. • APP had etoposide on shortage due to increased demand. • Ben Venue voluntarily suspended all manufacturing and distribution in mid-November, 2011. Product will become available in stages as production resumes. • Bedford Laboratories has multiple products affected by this suspension of manufacturing. Availability of all products, including those not manufactured at Ben Venue, is updated as information changes on the Bedford Laboratories website. • Accord could not provide a reason for the shortage. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=652 Source: www.ashp.org Doxycycline Hyclate Injection March 20, 2012 Products Affected - Description Doxycycline hyclate injection, Bedford 100 mg vial (NDC 55390-0110-10) Reason for the Shortage • Ben Venue voluntarily suspended all manufacturing and distribution in mid-November, 2011 on a temporary basis for maintenance and requalification of equipment. Product will become available in stages as production resumes. • Bedford Laboratories has temporarily suspended the distribution of Ben Venue Laboratories manufactured products. Availability of products is updated on the Bedford Laboratories website. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=431 Source: www.ashp.org Dextroamphetamine Tablets March 20, 2012 Products Affected - Description Dextroamphetamine tablets, Teva 5 mg tablets, 100 count (NDC 00555-0952-02) 10 mg tablets, 100 count (NDC 00555-0953-02) Reason for the Shortage • Teva has dextroamphetamine tablets and all other amphetamine products on back order due to a raw material shortage. • Teva is the sole manufacturer of dextroamphetamine tablets. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=853 Source: www.ashp.org 50
Daunorubicin Hydrochloride Injection March 20, 2012 Products Affected - Description Daunorubicin hydrochloride solution for injection, 5 mg/mL, Bedford 4 mL single-dose vial (NDC 55390-0108-10) 4 mL single-dose vial, Novaplus (NDC 55390-0142-10) 10 mL single-dose vial (NDC 55390-0108-01) Daunorubicin hydrochloride lyophilized powder for injection, Bedford 20 mg single-dose vial, package of 10, Novaplus (NDC 55390-0805-10) Cerubidine lyophilized powder for injection, Bedford 20 mg single-dose vial, package of 10 (NDC 55390-0281-10) Reason for the Shortage • Ben Venue voluntarily suspended all manufacturing and distribution in mid-November, 2011 on a temporary basis for maintenance and requalification of equipment. Product will become available in stages as production resumes. • Bedford Laboratories has multiple products affected by this suspension of manufacturing. Availability of all products, including those not manufactured at Ben Venue, is updated as information changes on the Bedford Laboratories website. • Teva had daunorubicin on shortage due to manufacturing issues. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=680 Source: www.ashp.org Dacarbazine Injection March 20, 2012 Products Affected - Description Dacarbazine powder for injection, APP 200 mg vial (NDC 63323-0128-20) Dacarbazine powder for injection, Hospira 100 mg vial (NDC 61703-0327-22) Dacarbazine powder for injection, Teva 200 mg vial, 1 count (NDC 00703-5075-01) 200 mg vial, 10 count (NDC 00703-5075-03) Dacarbazine powder for injection, Bedford 200 mg vial (NDC 55390-0090-10) Reason for the Shortage • Teva has dacarbazine on back order due to manufacturing delays. • Ben Venue voluntarily suspended all manufacturing and distribution in mid-November, 2011. Product will become available in stages as production resumes. • Bedford Laboratories has multiple products affected by this suspension of manufacturing. Availability of all products, including those not manufactured at Ben Venue, is updated as information changes on the Bedford Laboratories website. • Hospira has dacarbazine on shortage due to manufacturing delays. • APP has dacarbazine on shortage due to increased demand for the product. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=653 Source: www.ashp.org 51
Page 1 and 2: April 2012 Drug Information Update
Page 3 and 4: First-Time Generics GENERIC DRUG NA
Page 5 and 6: GENERAL ANESTHETICS, INJECTABLE MID
Page 7 and 8: Gruenhaupt, Mark R.Ph. Argus Health
Page 9 and 10: Statin Drugs - Drug Safety Communic
Page 11 and 12: Vytorin (ezetimibe/simvastatin) Tab
Page 13 and 14: low blood sugar (hypoglycemia) in p
Page 15 and 16: Some women with depression who beco
Page 17 and 18: Survival increased for all groups o
Page 19 and 20: finding that it also may reduce the
Page 21 and 22: Syringes (2 mL size), Rx only. NDC
Page 23 and 24: Patheon Pharmaceuticals Inc., Cinci
Page 25 and 26: 50-ct. bottles (NDC 0067-6238-50);
Page 27 and 28: PRODUCT (Class II) 1) Ventolin HFA
Page 29 and 30: Lot #: 0693, Exp: 10/2012 RECALLING
Page 31 and 32: 24 (Display case UPC# 3030045074923
Page 33 and 34: CODE Lot # 139961 RECALLING FIRM/MA
Page 35 and 36: Reason for the Shortage • Teva co
Page 37 and 38: Reason for the Shortage • Ben Ven
Page 39 and 40: Products Affected - Description Gan
Page 41 and 42: 37.5 mg/25 mg, 1000 count (NDC 0078
Page 43 and 44: Acyclovir tablets, Major 400 tablet
Page 45 and 46: 500 mg, 100 count (NDC 63304-0726-0
Page 47 and 48: 750 mg tablets, 100 count (NDC 1013
Page 49: • Bedford Laboratories has multip
Page 53 and 54: Ciprofloxacin Immediate-Release Tab
Page 55 and 56: • APP had tobramycin 40 mg/mL pre
Page 57 and 58: • Ben Venue voluntarily suspended
Page 59 and 60: 50 mg/mL, 10 mL vial, package of 10
Page 61 and 62: 2 mL vial, preservative-free (NDC 6
Page 63 and 64: 5 mg single dose vial, package of 1
Page 65 and 66: 20 mL glass ampule, sterile pack (N
Page 67 and 68: 2 mL iSecure syringe (NDC 00406-112
Page 69 and 70: Lidocaine 0.5% Xylocaine 0.5% injec
Page 71 and 72: • Teva discontinued all ciproflox
Page 73 and 74: Nicardipine hydrochloride injection
Page 75 and 76: Article link: http://www.ashp.org/D
Page 77 and 78: • Apotex had metformin products u
Page 79: • Covis purchased all rights to F

April 2012 Drug Information Update - Pharmacy Benefits ...

Create successful ePaper yourself

Delete template?

Save as template?